Mitoxantrone, methotrexate and chlorambucil in metastatic breast cancer, a combination with relatively low subjective toxicity.
Thirty-three patients with metastatic breast cancer received 135 cycles of chemotherapy consisting of mitoxantrone, methotrexate and chlorambucil. Forty-eight per cent of the patients achieved a partial response, and the median response duration was 8 months. Patchy alopecia was seen in 10 patients, but only 2 required a wig. In approximately half of the cycles, there were no complaints of nausea or vomiting. Nausea only was recorded in 27% of the cycles; nausea and vomiting in 26%. This combination regimen is active with a low degree of subjective toxicity.
Burghouts
J T
JT
Department of Internal Medicine, Groot Ziekengasthuis, 's-Hertogenbosch.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002699:Chlorambucil / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009362:Neoplasm Metastasis
D002699:Chlorambucil; D008942:Mitoxantrone; D008727:Methotrexate